|
China has included 119 more kinds of drugs in its national medical
insurance reimbursement list, delivering greater price cuts and
benefiting more people, the National Healthcare Security Administration
(NHSA) said at a press conference Monday. Ninety-six of the new additions to the list are exclusive drugs that
offer lower prices through negotiation and 16 were newly put on the
market this year, the NHSA said. Altogether, a record number of 162 drugs on the list were negotiated
for price reduction. A deal was reached for 119 of the drugs, with their
prices dropping an average of 50.64 percent. The inclusions also helped expand the scope of reimbursement to cover
more diseases including COVID-19. So far, all the medicines listed in
China's latest diagnosis and treatment scheme for COVID-19 have been
added to the reimbursement list, the NHSA said. China currently has 2,800 kinds of medicines on the medicare
reimbursement list, including 1,374 traditional Chinese patent
medicines. Enditem
| 
Related News
